drugset / Trial / NCT05800587
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Timeline
- Start
- 2023-02-22
- Primary completion
- 2028-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Lurbinectedin | Other / unclassified | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Topotecan | Small molecule | — | — |